Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 4/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | GALR1 | P47211 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607370 | 0.92 | GALR1 (0.39) | GALR1TPH1ADORA2AADORA1 | |
| SCHEMBL5554034 | 0.91 | GALR1 (0.38) | GALR1TPH1ADORA2AADORA1 | |
| SCHEMBL6427958 | 0.89 | GALR1 (0.33) | GALR1TPH1ADORA2AADORA1 | |
| SCHEMBL6428528 | 0.89 | GALR1 (0.35) | GALR1 | |
| SCHEMBL6428224 | 0.87 | CCNK (0.33) | GALR1ADORA2AADORA1 | |
| SCHEMBL5553495 | 0.85 | MAPK1 (0.34) | GALR1 | |
| SCHEMBL5553512 | 0.85 | MAPK1 (0.39) | PTGS2GALR1 | |
| SCHEMBL6231925 | 0.84 | TLR7 (0.34) | GALR1TPH1 | |
| SCHEMBL6429682 | 0.83 | MAPK1 (0.32) | GALR1 | |
| SCHEMBL5553561 | 0.82 | SMN1; SMN2 (0.37) | ADRA2AMCHR1NPY5RPTGS2GALR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | ADRA2A 3445/4885MCHR1 3271/4885NPY5R 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.